Journal: Advanced Science

Article Title: Three‐Year Follow‐Up of Neoadjuvant Tislelizumab with Chemotherapy in Locally Advanced Gastric and Gastroesophageal Junction Adenocarcinoma: Revealing Cancer‐Associated Fibroblast Heterogeneity Corresponding to PD‐1 Blockade Efficacy

doi: 10.1002/advs.202508433

Figure Lengend Snippet: eCAFs and iCAFs showed different reactions to immunotherapy. a) UMAP visualization of CAF subtypes identified in LAGC tissues. b) Proportions of CAF subtypes in responders and non‐responders. c) UMAP feature plots showing the expression levels of representative marker genes (ACTA2, COL14A1, FAP, and SLIT2) in CAF subtypes. d) GO functional enrichment analysis of iCAFs, eCAFs, and myCAFs. e) KEGG pathway enrichment analyses of iCAFs, eCAFs, and myCAFs. f) GSEA of iCAFs, eCAFs, and myCAFs. GO, gene ontology; KEGG, Kyoto Encyclopedia of Genes and Genomes; GSEA, gene set enrichment analysis; CAF, cancer‐associated fibroblast; iCAF, inflammatory CAF; eCAF, extracellular matrix‐related CAF; myCAF, myofibroblastic CAF; LAGC, locally advanced gastric cancer.

Article Snippet: Multiplex immunohistochemical (IHC) staining was performed using the Opal 5‐color kit (Akoya Bioscience, NEL801001KT) to evaluate CFD (GB12045, Servicebio, 1:5000, Opal 440), COL14A1 (AF0573, Affinity Biosciences, 1:2000, Opal 488), FAP (11779‐1‐AP, 1:2000, Opal 555), SLIT2 (20217‐1‐AP, ProteinTech, 1:2000, Opal 647), CXCL14 (10468‐1‐AP, ProteinTech, 1:1000, Opal 647) and POSTN (66491‐1‐Ig, 1:1000, Opal 488).

Techniques: Expressing, Marker, Functional Assay

Journal: Advanced Science

Article Title: Three‐Year Follow‐Up of Neoadjuvant Tislelizumab with Chemotherapy in Locally Advanced Gastric and Gastroesophageal Junction Adenocarcinoma: Revealing Cancer‐Associated Fibroblast Heterogeneity Corresponding to PD‐1 Blockade Efficacy

doi: 10.1002/advs.202508433

Figure Lengend Snippet: The different CAF subtypes involved the immune microenvironment. a) UMAP of all spots (n = 29808) from nine GC primary samples. b) The proportion of cell types in all samples. c) Violin plots showing the expression of immune‐stimulating factors CXCL8, CXCL9, CXCL10, CXCL11, CCL4, CCL5, and IFNG. d) Heatmap for AUcell scores of immune pathways and CAF subtypes (iCAFs and eCAFs) across GC samples. e) The spatial representation of cell type niches in STAD#2 (immunogenic GC) and STAD#5 (non‐immunogenic GC). f) The expression level of iCAFs in spots of STAD#2 and STAD#5. g) The spatial representation of iCAFs in spots of STAD#2 and STAD#5. h) Violin plots for the expression of POSTN, CXCL14, CFD, CD34, SLIT2, FAP, and ACTA2 in all GC samples. i) The spatial representation of CD8+ T cells in spots of STAD#2, STAD#8, (immunogenic GC) STAD#5, and STAD#6 (non‐immunogenic GC). * p < 0.05, ** p < 0.01, *** p < 0.001. CAF, cancer‐associated fibroblast; iCAF, inflammatory CAF; eCAF, extracellular matrix‐related CAF; GC, gastric cancer.

Article Snippet: Multiplex immunohistochemical (IHC) staining was performed using the Opal 5‐color kit (Akoya Bioscience, NEL801001KT) to evaluate CFD (GB12045, Servicebio, 1:5000, Opal 440), COL14A1 (AF0573, Affinity Biosciences, 1:2000, Opal 488), FAP (11779‐1‐AP, 1:2000, Opal 555), SLIT2 (20217‐1‐AP, ProteinTech, 1:2000, Opal 647), CXCL14 (10468‐1‐AP, ProteinTech, 1:1000, Opal 647) and POSTN (66491‐1‐Ig, 1:1000, Opal 488).

Techniques: Expressing

Journal: Advanced Science

Article Title: Three‐Year Follow‐Up of Neoadjuvant Tislelizumab with Chemotherapy in Locally Advanced Gastric and Gastroesophageal Junction Adenocarcinoma: Revealing Cancer‐Associated Fibroblast Heterogeneity Corresponding to PD‐1 Blockade Efficacy

doi: 10.1002/advs.202508433

Figure Lengend Snippet: Multi‐IF confirmed the duality of CAFs in immunotherapy. a,b) Multiplexed immunofluorescence staining of FAP, SLIT2, CFD, and COL14A1 in LAGC tissues of responders and non‐responders treated with immunotherapy. Multiplexed immunofluorescence assays were performed twice on tumor samples following assay optimization. c–f) Quantification of PCP for COL14A1, FAP, SLIT2, and CFD in patients with LAGC stratified by TRGs. g) Kaplan‐Meier analysis of PFS based on different expression levels of COL14A1, FAP, SLIT2, and CFD in patients receiving immunotherapy. h) Kaplan‐Meier analysis of OS according to the expression levels of COL14A1, FAP, SLIT2, and CFD in patients receiving immunotherapy. PCP, percentage of positive cells; TRG 0, (complete pathological response in the primary tumor and lymph nodes, no residual tumor cells), TRG 1, (near‐complete response, ≤10% residual tumor cells), TRG 2, (partial response, 10–50% residual tumor cells), and TRG 3, (poor or no response, ≥50% residual tumor cells). PFS, prognosis‐free survival; OS, overall survival; * p < 0.05, ** p < 0.01, *** p < 0.001.

Article Snippet: Multiplex immunohistochemical (IHC) staining was performed using the Opal 5‐color kit (Akoya Bioscience, NEL801001KT) to evaluate CFD (GB12045, Servicebio, 1:5000, Opal 440), COL14A1 (AF0573, Affinity Biosciences, 1:2000, Opal 488), FAP (11779‐1‐AP, 1:2000, Opal 555), SLIT2 (20217‐1‐AP, ProteinTech, 1:2000, Opal 647), CXCL14 (10468‐1‐AP, ProteinTech, 1:1000, Opal 647) and POSTN (66491‐1‐Ig, 1:1000, Opal 488).

Techniques: Immunofluorescence, Staining, Expressing

Journal: Translational Andrology and Urology

Article Title: Systematic analysis of UBE2D3 and its association with prognosis, tumor microenvironment, and drug sensitivity in renal clear cell carcinoma

doi: 10.21037/tau-2025-427

Figure Lengend Snippet: Copper metabolism related genes DLD and UBE2D3 act as protective factors in KIRC. (A) The OS Kaplan-Meier curve of DLD genes. (B) The ROC curve of DLD gene. (C) The Kaplan-Meier curve (OS) of UBE2D3 gene. The ROC curve of UBE2D3 gene (D) shows the differential expression of UBE2D3 gene at different T stages (E). (F) The expression differences of gene UBE2D3 in different G stages. (G) The calibration curve of the Norman plot is used to predict 1-, 3-, and 5-year survival rates. (H) By drawing a line graph, we predicted the OS period over a time range of 1-, 3-, and 5-year. Each risk factor corresponds to a point axis by drawing a line on the graph. *, P<0.05; **, P<0.01; ***, P<0.001. AUC, area under the curve; CI, confidence interval; G, grade; H, high; HR, hazard ratio; KIRC, kidney renal clear cell carcinoma; L, low; OS, overall survival; ROC, receiver operating characteristic; T, tumor.

Article Snippet: The paraffin-embedded tissue sections were deparaffinized overnight at 4 °C with rabbit anti UBE2D3 (15475-1-AP, Protein, (15475-1-AP, Proteintech, Wuhan, China) at a dilution ratio of 1:400.

Techniques: Quantitative Proteomics, Expressing

Journal: Translational Andrology and Urology

Article Title: Systematic analysis of UBE2D3 and its association with prognosis, tumor microenvironment, and drug sensitivity in renal clear cell carcinoma

doi: 10.21037/tau-2025-427

Figure Lengend Snippet: UBE2D3 functional analysis. (A) UBE2D3 gene expression risk prognostic model. (B) UBE2D3 protein interaction network diagram. (C) Volcano plot based on UBE2D3. (D) GO analysis of differential genes between high and low UBE2D3 groups. (E) KEGG enrichment analysis between high and low UBE2D3 groups. (F) GSEA signal pathway enrichment analysis based on UBE2D3 expression. BP, biological process; CC, cellular component; ES, Enrichment Score; GO, Gene Ontology; GSEA, Gene Set Enrichment Analysis; KEGG, Kyoto Encyclopedia of Genes and Genomes; MF, molecular function; NP, nominal P value.

Article Snippet: The paraffin-embedded tissue sections were deparaffinized overnight at 4 °C with rabbit anti UBE2D3 (15475-1-AP, Protein, (15475-1-AP, Proteintech, Wuhan, China) at a dilution ratio of 1:400.

Techniques: Functional Assay, Gene Expression, Expressing

Journal: Translational Andrology and Urology

Article Title: Systematic analysis of UBE2D3 and its association with prognosis, tumor microenvironment, and drug sensitivity in renal clear cell carcinoma

doi: 10.21037/tau-2025-427

Figure Lengend Snippet: Correlation analysis between UBE2D3 expression and immune cells. (A) Using CIBERSORT method to explore the differences in expression levels of 22 immune cells at different levels of UBE2D3. (B) Correlation analysis between 22 different immune cells. (C) Correlation analysis between UBE2D3 expression levels and biological markers between B cell, Th cell, CD8 + T cell, and DC. (D) Correlation analysis between UBE2D3 expression levels and biological markers between M2 macrophages. (E) Correlation analysis between UBE2D3 expression levels and biological markers between CAF, MDSC, and TAM. (F) Expression of UBE2D3 Correlation analysis chart between levels and biological markers of T exhausted cell, Treg T cell, and macrophages. *, P<0.05; **, P<0.01; ***, P<0.001; ****, P<0.0001. CAF, cancer-associated fibroblast; CIBERSORT, Cell-Identification By Estimating Relative Subsets Of RNA Transcripts; MDSC, myeloid-derived suppressor cells; TAM, tumor-associated macrophages.

Article Snippet: The paraffin-embedded tissue sections were deparaffinized overnight at 4 °C with rabbit anti UBE2D3 (15475-1-AP, Protein, (15475-1-AP, Proteintech, Wuhan, China) at a dilution ratio of 1:400.

Techniques: Expressing, Derivative Assay

Journal: Translational Andrology and Urology

Article Title: Systematic analysis of UBE2D3 and its association with prognosis, tumor microenvironment, and drug sensitivity in renal clear cell carcinoma

doi: 10.21037/tau-2025-427

Figure Lengend Snippet: UBE2D3 affects the tumor immune microenvironment. (A) Using TIMER database to evaluate the correlation between UBE2D3 and immune cells. (B) Box plot shows the distribution of each immune subgroup in KIRC at each copy number state, comparing the infiltration levels of each SCNA category with normal levels. *, P<0.05; **, P<0.01; ***, P<0.001; ****, P<0.0001. KIRC, kidney renal clear cell carcinoma; SCNA, Somatic Copy-number Alteration; TCGA, The Cancer Genome Atlas; TIMER, Tumor Immune Estimation Resource.

Article Snippet: The paraffin-embedded tissue sections were deparaffinized overnight at 4 °C with rabbit anti UBE2D3 (15475-1-AP, Protein, (15475-1-AP, Proteintech, Wuhan, China) at a dilution ratio of 1:400.

Techniques:

Journal: Translational Andrology and Urology

Article Title: Systematic analysis of UBE2D3 and its association with prognosis, tumor microenvironment, and drug sensitivity in renal clear cell carcinoma

doi: 10.21037/tau-2025-427

Figure Lengend Snippet: Expression and infiltration of UBE2D3 among different cell populations in the single-cell sequencing dataset. (A) The expression of UBE2D3 in different cells in different datasets. (B) The distribution of GSE139555 cells in the scRNA seq dataset. (C) The distribution of 11 annotation groups in the scRNA seq dataset. (D) The distribution of UBE2D3 in different cells in the scRNA seq dataset. (E) The expression differences of UBE2D3 in different cells between KIRC patients and normal individuals. (F) The expression differences of UBE2D3 in different tumor stages and cells. GSE, GEO Series Accession Number; KIRC, kidney renal clear cell carcinoma; N.S., not significant; NAT, normal adjacent tissue; PBMC, peripheral blood mononuclear cells; scRNA seq, single-cell RNA sequencing; TNM, tumor-node-metastasis; TPM, transcripts per million.

Article Snippet: The paraffin-embedded tissue sections were deparaffinized overnight at 4 °C with rabbit anti UBE2D3 (15475-1-AP, Protein, (15475-1-AP, Proteintech, Wuhan, China) at a dilution ratio of 1:400.

Techniques: Expressing, Single Cell, Sequencing, RNA Sequencing

Journal: Translational Andrology and Urology

Article Title: Systematic analysis of UBE2D3 and its association with prognosis, tumor microenvironment, and drug sensitivity in renal clear cell carcinoma

doi: 10.21037/tau-2025-427

Figure Lengend Snippet: UBE2D3 mutation and methylation analysis. (A) Methylation level analysis of UBE2D3 between tumor and normal groups. (B) Methylation level analysis of UBE2D3 in normal group and different stage. (C) Methylation level analysis of UBE2D3 in normal group and different grade stages. (D) Methylation level analysis of UBE2D3 in normal group and different N-stage. (E) Heat map analysis of DNA methylation in the MethSurv database. (F) Correlation between CNV and expression level of UBE2D3. (G) Correlation between CNV level of UBE2D3 and survival. *, P<0.05; **, P<0.01; ***, P<0.001. CNV, copy number variation; Cor, correlation; DFI, disease-free interval; DSS, disease-specific survival; FDR, false discovery rate; KIRC, kidney renal clear cell carcinoma; mRNA, messenger RNA; N, node; OS, overall survival; PFS, progression-free survival; RSEM, RNA-seq by expectation-maximization; TCGA, The Cancer Genome Atlas.

Article Snippet: The paraffin-embedded tissue sections were deparaffinized overnight at 4 °C with rabbit anti UBE2D3 (15475-1-AP, Protein, (15475-1-AP, Proteintech, Wuhan, China) at a dilution ratio of 1:400.

Techniques: Mutagenesis, Methylation, DNA Methylation Assay, Expressing, RNA Sequencing

Journal: Translational Andrology and Urology

Article Title: Systematic analysis of UBE2D3 and its association with prognosis, tumor microenvironment, and drug sensitivity in renal clear cell carcinoma

doi: 10.21037/tau-2025-427

Figure Lengend Snippet: Analyze the drug sensitivity of UBE2D3 in KIRC and predict the IC 50 of the drug. (A) Vincristine. (B) Bosutinib. (C) Ambazone. (D) Finefloxacin. (E) Anagrelide. (F) Meclizine. (G) Dabrafenib. (H) Navitoclax. (I) Propranolol. ***, P<0.001. IC 50 , median inhibitory concentration; KIRC, kidney renal clear cell carcinoma.

Article Snippet: The paraffin-embedded tissue sections were deparaffinized overnight at 4 °C with rabbit anti UBE2D3 (15475-1-AP, Protein, (15475-1-AP, Proteintech, Wuhan, China) at a dilution ratio of 1:400.

Techniques: Concentration Assay

Journal: Translational Andrology and Urology

Article Title: Systematic analysis of UBE2D3 and its association with prognosis, tumor microenvironment, and drug sensitivity in renal clear cell carcinoma

doi: 10.21037/tau-2025-427

Figure Lengend Snippet: Molecular docking patterns of key drugs and core targets. (A) Vincristine binding to P113 isosite. (B) Bosutinib binding to S100 isosite. (C) Ambazone binding to L89 isosite. (D) Finefloxacin binding to P95 isosite. (E) Anagrelide binding to T98 isosite. (F) Meclizine binding to P57 isosite. (G) Dabrafenib binding to K63 isosite. (H) Navitoclax binding to A68 isosite. (I) Propanol binding to E9 isosite. (J) Different small molecule drugs binding to target UBE2D3 Vina score comparison.

Article Snippet: The paraffin-embedded tissue sections were deparaffinized overnight at 4 °C with rabbit anti UBE2D3 (15475-1-AP, Protein, (15475-1-AP, Proteintech, Wuhan, China) at a dilution ratio of 1:400.

Techniques: Binding Assay, Comparison

Journal: Translational Andrology and Urology

Article Title: Systematic analysis of UBE2D3 and its association with prognosis, tumor microenvironment, and drug sensitivity in renal clear cell carcinoma

doi: 10.21037/tau-2025-427

Figure Lengend Snippet: Immunostaining image of UBE2D3 . (A) Expression of UBE2D3 in Para cancer (100×). (B) Expression of UBE2D3 in Para cancer (200×). (C) Expression of UBE2D3 in KIRC (100×). (D) Expression of UBE2D3 in KIRC (200×). (E) IHC staining statistics of UBE2D3 in KIRC and adjacent tissues. **, P<0.01. AOD, average optical density; IHC, immunohistochemistry; KIRC, kidney renal clear cell carcinoma.

Article Snippet: The paraffin-embedded tissue sections were deparaffinized overnight at 4 °C with rabbit anti UBE2D3 (15475-1-AP, Protein, (15475-1-AP, Proteintech, Wuhan, China) at a dilution ratio of 1:400.

Techniques: Immunostaining, Expressing, Immunohistochemistry

Journal: Cell Discovery

Article Title: Complement 5a receptor 2 attenuates diabetic kidney disease by promoting mitochondria-associated endoplasmic reticulum membrane formation mediated by PSS-MFN2 interaction

doi: 10.1038/s41421-026-00873-w

Figure Lengend Snippet: a Representative IHC images of ADRP staining (scale bars = 60 μm). b Quantitative analysis of ADRP staining in different groups of mice ( n = 8 per group). c ‒ e Representative images and quantitative analysis of Oil Red O staining and Nile Red staining in different groups of mice ( n = 8 per group) (scale bars = 200 μm). c , f Representative TEM micrographs and quantitative analysis of lipid droplet areas in renal tubular epithelial cells (TECs) from different groups of mice ( n = 5 per group) (scale bars = 2 µm). g , h Representative TEM micrographs and quantification of dysmorphic mitochondria in renal TECs from different groups of mice ( n = 5 per group) (scale bars = 2 µm). i – l Representative western blotting images and quantitative analysis of ER stress markers, including XBP-1s, p-EIF2α, EIF2α, and CHOP, in different groups of mice ( n = 6 per group). m ‒ o Representative images and quantitative analysis of Oil Red O-stained and Nile Red-stained areas of TCMK-1 cells subjected to different treatments ( n = 3 independent replicates) (scale bars = 50 µm). p The mitochondrial oxygen consumption rates (OCRs) in different groups of TCMK-1 cells were measured via an extracellular flux analyzer. Representative data ( n = 3 independent replicates) are shown. q , r Quantified OCR parameters are presented as the mean ± SD. Statistical analysis was performed by one-way ANOVA (Tukey’s multiple comparisons test). ns not significant; * P < 0.05; ** P < 0.01; *** P < 0.001; **** P < 0.0001.

Article Snippet: The membranes were blocked with 5% skim milk and then incubated with primary antibodies against C5aR2 (sc-515734; Santa Cruz Biotechnology), PSS1 (ab157222; Abcam), PSS2 (ARP49961_P050; Aviva Systems Biology Corporation), MFN2 (12186-1-AP; Proteintech), XBP-1s (143F; BioLegend), p-EIF2α (28740-1-AP; Proteintech), EIF2α (11170-1-AP; Proteintech), CHOP (15204-1-AP; Proteintech), COX IV (11242-1-AP; Proteintech), calnexin (10427-2-AP; Proteintech), ERK1/2 (4695; Cell Signaling Technology), p-ERK1/2 (4370; Cell Signaling Technology), HA (ab9110, Abcam), FLAG (ab213519, Abcam), α-tubulin (HRP-80762; Proteintech), and β-actin (Ac028; ABclonal).

Techniques: Staining, Western Blot

Journal: Cell Discovery

Article Title: Complement 5a receptor 2 attenuates diabetic kidney disease by promoting mitochondria-associated endoplasmic reticulum membrane formation mediated by PSS-MFN2 interaction

doi: 10.1038/s41421-026-00873-w

Figure Lengend Snippet: a Schematic illustration of the experimental design for establishing a dose gradient of P59 administered via subcutaneous injection in db/db mice. b uACR in different groups of mice ( n = 6 per group). c Representative images of PAS staining of the glomeruli and tubulointerstitium (scale bars = 200 μm). d , e Quantitative analysis of mesangial matrix expansion ( d ) and the tubulointerstitial injury index ( e ) in different groups of mice ( n = 6 per group). f UMAP plot showing thirteen populations of kidney cells in vehicle-treated m/m mice, vehicle-treated db/db mice, and P59-treated db/db mice ( n = 3 per group). Each dot corresponds to a single cell and is colored according to the cell type. g Dot plot showing the expression of genes characteristic of each cell population in the scRNA-seq data. h GO enrichment analysis of DEGs between vehicle-treated db/db mice and P59-treated db/db mice. -Log 10 (adjusted P value) > 1.3 was used as the cutoff. i , j Representative images and quantitative analysis of Oil Red O-stained areas in different groups of mice ( n = 6 per group ) . Scale bars = 100 µm. i , k Representative TEM micrographs and quantitative analysis of LD areas in TECs from different groups of mice ( n = 6 per group) (scale bars = 5 µm). l , m Representative TEM micrographs and quantification of the number of dysmorphic mitochondria in TECs in different groups of mice ( n = 6 per group) (scale bars = 5 µm). n Representative western blotting images and quantitative analysis of ER stress markers (XBP-1s, p-EIF2α, EIF2α, and CHOP) in different groups of mice ( n = 6 per group ) . The data in the graphs are presented as the means ± SD. The data were analyzed by two-sided one-way ANOVA with Tukey’s test. ns not significant; ** P < 0.01; *** P < 0.001; **** P < 0.0001.

Article Snippet: The membranes were blocked with 5% skim milk and then incubated with primary antibodies against C5aR2 (sc-515734; Santa Cruz Biotechnology), PSS1 (ab157222; Abcam), PSS2 (ARP49961_P050; Aviva Systems Biology Corporation), MFN2 (12186-1-AP; Proteintech), XBP-1s (143F; BioLegend), p-EIF2α (28740-1-AP; Proteintech), EIF2α (11170-1-AP; Proteintech), CHOP (15204-1-AP; Proteintech), COX IV (11242-1-AP; Proteintech), calnexin (10427-2-AP; Proteintech), ERK1/2 (4695; Cell Signaling Technology), p-ERK1/2 (4370; Cell Signaling Technology), HA (ab9110, Abcam), FLAG (ab213519, Abcam), α-tubulin (HRP-80762; Proteintech), and β-actin (Ac028; ABclonal).

Techniques: Injection, Staining, Single Cell, Expressing, Western Blot

Journal: bioRxiv

Article Title: Comparative analysis of wavelength-specific UV stress granule formation

doi: 10.64898/2026.03.15.711948

Figure Lengend Snippet: Representative images of SG formation by G3BP1 and TIA1 signals in wt U2OS cells treated as indicated. Cells were either untreated, treated with 250μM As III for 1h, or exposed to 15mJ/cm 2 of UV. UV samples were harvested and processed for imaging 4 hours after exposure. Yellow arrows indicate SGs. Scale bar = 20μm.

Article Snippet: The following antibodies were used in this study; G3BP1 (Proteintech® 13057 (rabbit) and 66486 (mouse)), S6 Ribosomal protein (RPS6) (ABclonal A6058), TIA1 (Proteintech® 12133), RACK1 (Proteintech® 66940), TRAF2 (Proteintech® 26846 (rabbit) 67315 (mouse)), Geminin (Proteintech® 10802), DHX9 (Proteintech®17721), cytokeratin 8 (Invitrogen, 06318), and eIF3n (Santa Cruz, 137214).

Techniques: Imaging

Journal: bioRxiv

Article Title: Comparative analysis of wavelength-specific UV stress granule formation

doi: 10.64898/2026.03.15.711948

Figure Lengend Snippet: (A) Representative images of SG formation by G3BP1 and TIA1 signals in HaCaT cells treated as indicated. Cells were either untreated, treated with 250μM As III for 1h, or exposed to 15mJ/cm 2 of UV. UV samples were harvested and processed for imaging 4 hours after exposure. (B) Quantification of SG formation by G3BP1 and TIA1 signals in wt U2OS, HaCaT, and wt MEF cells treated as indicated. Cells were either untreated, treated with 250μM As III for 1h, or exposed to 15mJ/cm 2 of UV. UV samples were harvested and processed for imaging 4 hours after exposure. At least 250 cells and 3 fields of view were scored to calculate percent SG formation. n =3; error bars are ±SD; ns P > 0.05, ** P ≤ 0.01, **** P ≤ 0.0001 by one-way ANOVA and Dunnett’s post-hoc test. (C) Quantification of SG formation by G3BP1 and TIA1 signals in wt U2OS cells treated as indicated. Cells were either untreated, treated with 250μM As III for 1h, or exposed to 150mJ/cm 2 of UV. UV samples were harvested and processed for imaging 4 hours after exposure. At least 250 cells and 3 fields of view were scored to calculate percent SG formation. n =3; error bars are ±SD; ns P > 0.05, **** P ≤ 0.0001 by one-way ANOVA and Dunnett’s post-hoc test. Scale bar = 20μm.

Article Snippet: The following antibodies were used in this study; G3BP1 (Proteintech® 13057 (rabbit) and 66486 (mouse)), S6 Ribosomal protein (RPS6) (ABclonal A6058), TIA1 (Proteintech® 12133), RACK1 (Proteintech® 66940), TRAF2 (Proteintech® 26846 (rabbit) 67315 (mouse)), Geminin (Proteintech® 10802), DHX9 (Proteintech®17721), cytokeratin 8 (Invitrogen, 06318), and eIF3n (Santa Cruz, 137214).

Techniques: Imaging